Blueprint Biosecurity

Blueprint published a conventional GUV overview blog post, describing what conventional germicidal ultraviolet is, how it works, and what is needed for broader deployment, and directing readers to a downloadable one-pager.

Blueprint announced a Collaborative Research and Development Agreement (CRADA) with EPA, describing multi-year testing at EPA’s Aerosol Test Facility to evaluate interventions including far-UVC and glycol vapors (and additional antimicrobial vapors) under conditions intended to inform evidence and potential future deployment guidance.

Blueprint published a Q&A blog post outlining what glycol vapors are, why the organization is evaluating specific glycols, how they may differ from other air-treatment interventions, current evidence, and key research gaps, including safety considerations relevant to occupied spaces.

Blueprint announced over $1.7M in grants through its FILTER program to evaluate drivers and mechanisms of respirator filter degradation (FFRs and elastomeric half-mask respirators) under real-world use and routine workplace conditions, with an expected readout in mid-2027.

Blueprint published an overview describing far-UVC research funded to date and organizing the portfolio across effectiveness, safety, and real-world deployment, including work tied to clinical trial protocol development (FIR-Protocol) and other funded efforts.

Blueprint published a blog post discussing how historical evidence and real-world transmission models could help build the case for far-UVC as a pandemic countermeasure, anchored in the context of tuberculosis (TB) transmission testing approaches and the Airborne Infection Research (AIR) facility.